Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | TYMP | P19971 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24205261 | 0.83 | TSHR (0.44) | TSHRALDH1A1GPR84KDM4EL3MBTL1 | |
| SCHEMBL26035421 | 0.81 | ALDH1A1 (0.42) | TSHRALDH1A1CYP3A4HPGDGPR84 | |
| SCHEMBL28004594 | 0.80 | TSHR (0.56) | TSHRALDH1A1CYP3A4HPGDGPR84 | |
| SCHEMBL26035322 | 0.79 | TSHR (0.47) | TSHRALDH1A1CYP3A4HPGDKDM4E | |
| SCHEMBL29061665 | 0.79 | TSHR (0.53) | TSHRALDH1A1CYP3A4HPGDKDM4E | |
| SCHEMBL27704679 | 0.79 | TSHR (0.53) | TSHRALDH1A1CYP3A4HPGDGPR84 | |
| SCHEMBL24205029 | 0.77 | ALDH1A1 (0.51) | TSHRALDH1A1CYP3A4L3MBTL1 | |
| SCHEMBL24205030 | 0.77 | ALDH1A1 (0.51) | TSHRALDH1A1CYP3A4L3MBTL1 | |
| SCHEMBL25368913 | 0.77 | ALDH1A1 (0.51) | TSHRALDH1A1CYP3A4L3MBTL1 | |
| SCHEMBL26035014 | 0.77 | ALDH1A1 (0.51) | TSHRALDH1A1CYP3A4L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230273455-A1 | OPTICALLY ACTIVE DEVICES | JOHNSON & JOHNSON SURGICAL VISION INC (US) | 2023-08-31 | — | — | US | disclosed |
| WO-2022012798-A1 | OPTICALLY ACTIVE DEVICES | MERCK PATENT GMBH (DE) | 2022-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230273455-A1 | OPTICALLY ACTIVE DEVICES | PDE6C, PDE6A, PDE6D | TSHR 4592/4885ALDH1A1 311/4885CYP3A4 2513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.